• Description
  • Preclinical
  • Clinical
  • Presentations
  • References


Otlertuzumab (originally known as TRU-016) is a humanized monospecific ADAPTIR™ molecule that targets CD37. CD37 is a cell surface protein expressed on normal and transformed B cells that has been implicated in diverse cellular processes including cell adhesion, proliferation, differentiation, motility, and tumor invasion.

Otlertuzumab mediates death of CD37-expressing cells through various mechanisms including direct cell death, antibody-dependent cell-mediated cytotoxicity (ADCC), and phagocytosis. Otlertuzumab is being investigated for the treatment of chronic lymphocytic leukemia (CLL) in combination with complementary drugs.